

# Gemini Stock Analysis Report

---

Based on the analysis of the "Stock Detailed Analysis Report" for **LUPIN.NS**, here is the positional trading assessment.

---

## Step 1: Audit the Data

### • Data Present:

- **Price Action:** Daily (3-year) and Weekly charts.
- **Moving Averages:** 20, 50, 200 EMAs and crossover analysis.
- **Trend Indicators:** Supertrend (Multi-timeframe), MACD, Bollinger Bands, Volatility Squeeze.
- **Momentum/Oscillators:** RSI (Relative Strength Index).
- **Volume Analysis:** Volume Moving Averages, Distribution Days count.
- **Relative Strength:** RS Score, RS vs. Benchmark (CNXPHARMA).
- **Fundamentals:** Revenue, Net Income, ROE, EPS (Long and Short term).

### • Data Missing:

- Specific Level 2/Order Book data (not typical in PDF reports but useful).
- Fibonacci retracement levels (must be visually estimated).

• **Confidence Level: High.** The report provides a comprehensive technical and fundamental view, including conflicting signals (Distribution days vs. **Uptrend** status), allowing for a nuanced decision.

- *Note on Date:* The report bears a generated timestamp of **January 2026**. I will analyze this as if the current date is Jan 24, 2026, per the document's reality.
- 

## Step 2: Analyze the Setup

**Price Structure & Trend:**\* **Long-term:** **Bullish.** The stock is trading above the 200 EMA (2023.71) and the 50 EMA (2109.47).\* **Short-term:** Corrective/Consolidating. The price (2137.20) has dipped below the 20 EMA (2151.50). The stock is currently sandwiching between the 20 EMA (Resistance) and the 50 EMA (Support).\* **Volatility:** The Bollinger Bands are tightening (Squeeze detected on Page 15), indicating a large move is imminent. However, direction is currently ambiguous.

**Momentum & Signals:**\* **MACD:** **Bearish.** The MACD line is below the signal line, and the histogram is negative. Momentum is strengthening to the downside (Page 12).\* **RSI:** Neutral (49.01). It has cooled off from overbought levels but has not yet found a firm floor or bullish divergence.\* **Relative Strength:** Weakening. The RS Score is 55.2 ("Weakening Leader"), and the line against the Pharma index is trending down.\*

**Volume: Concerning.** Page 18 lists 5 "Distribution Days" between Jan 13 and Jan 21. This indicates institutional selling into the current consolidation.

**Confluence:**The setup is a "Pullback to Support" candidate. The confluence of the 50 EMA (~2109) and the daily Supertrend Support (~2097) provides a "floor." However, the distribution volume and bearish MACD suggest the floor might crack.

---

## Step 3: Formulate the Recommendation

**Recommendation: NO (Do not enter at current market price).**

# Gemini Stock Analysis Report

---

**Rationale:** Entering now is premature ("catching a falling knife"). While the long-term trend is up, the short-term momentum is explicitly bearish (MACD, sub-20 EMA price action). The high frequency of recent distribution days suggests significant selling pressure. We need confirmation that the 50 EMA support will hold and that buyers are stepping back in to reclaim momentum.

## Conditional Plan (Wait for Confirmation):

- **Condition to Buy:** The stock must close **above the 20 EMA** on the daily chart to confirm the correction is over and momentum has shifted back to bullish.
- **Entry Price: INR 2,155 - INR 2,160** (Strictly on a daily Close  $>$  20 EMA of 2151.50).
- **Stop Loss: INR 2,090** (Hard stop).
  - *Reasoning:* This places the stop below the 50 EMA (2109) and the Supertrend Support (2097). If these levels break, the intermediate uptrend is invalid.
- **Take Profit: INR 2,305 (Target 1)** and **INR 2,400 (Target 2)**.
  - *Reasoning:* Target 1 aligns with analyst estimates (Page 23) and recent resistance. Target 2 assumes a breakout from the volatility squeeze for a ~10-12% gain.

## News & Analyst Targets

To: Investment Committee  
From: Stock Research Desk  
Date: Sunday, January 25, 2026  
Subject: Research Update - Lupin Limited (LUPIN)

Here is the latest research update on Lupin Limited for the week ending January 25, 2026.

### 1) Latest News for LUPIN (Week of Jan 19-25, 2026)

- **Strategic Licensing Agreement for Semaglutide (Jan 21, 2026):** Lupin has signed a significant licensing and supply agreement with Galenicum Health, S.L.U. for injectable Semaglutide. This agreement covers 23 countries, expanding Lupin's footprint in the high-demand GLP-1 receptor agonist market (used for diabetes and weight loss). This is a major strategic positive, reinforcing their complex generic pipeline.
- **Strong ESG Rating Assigned (Jan 19, 2026):** Lupin received an ESG rating of **67 (Strong Category)** from *ESG Risk Assessments & Insights Limited*. This independent assessment highlights the company's robust environmental, social, and governance practices, which is increasingly critical for institutional holding eligibility.
- **Analyst Sentiment:** As of Jan 20, 2026, *MarketsMOJO* has maintained a "**Buy**" rating on the stock, citing strong quality grades, a low debt-to-equity ratio (0.10x), and attractive valuation metrics despite some short-term price volatility.

### 2) Brokerage Upgrades & Downgrades

- **FundsIndia (Jan 16, 2026):** Maintained a **Buy** rating with a revised target of **INR 2,543**, projecting an upside of roughly 19% from current levels.
- **MarketsMOJO (Jan 20, 2026):** Reaffirmed **Buy** rating. They highlight the company's "Very Attractive" valuation grade and "Good" financial trend.
- **Consensus View:** The broader analyst community remains "Outperform" to "Buy" on the stock. While there have been no major *downgrades* this specific week, the consensus price target has adjusted slightly to reflect recent market movements.

### 3) Other News Impacting LUPIN

# Gemini Stock Analysis Report

---

## • FDA Compliance Status (Mixed Bag):

- *Nagpur Unit-1:* Continue to view the **Zero Observations** status (received in Nov 2025) as a key stabilizer for their US supply chain.
- *Goa Facility:* The **7 Observations (Form 483)** received in late 2025 remain a "watch item." The market is awaiting the final resolution or EIR (Establishment Inspection Report) to de-risk this facility fully.
- **Financial Backdrop:** The sentiment continues to be supported by the strong Q2 FY26 performance (reported Nov 2025), where PAT surged 73% YoY. The market is currently positioning for Q3 results, expecting continued momentum in the US respiratory business.

## 4) Analyst Targets (Latest Available)

The following table summarizes the most recent price targets from major brokerages and consensus estimates as of January 2026.

Date	Brokerage / Firm	Rating	Target Price (INR)	Upside Potential*
25 Jan 2026	Consensus Estimate	Buy	2,306	~8%
16 Jan 2026	FundsIndia	Buy	2,543	~19%
25 Nov 2025	Geojit BNP Paribas	Buy	2,225	~4%
13 Nov 2025	Deven Choksey	Buy	2,404	~12%
11 Nov 2025	ICICI Direct	Buy	2,275	~6%
09 Nov 2025	ICICI Securities	Hold	1,950	(Downside)
07 Aug 2025	Sharekhan	Buy	2,400	~12%

\*Upside calculated based on the reference market price of ~INR 2,137 as of the latest close.

**Analyst Note:** The divergence between ICICI Securities (Hold) and FundsIndia (Buy) largely centers on valuation premiums and the speed of resolving the Goa facility's FDA observations. However, the Semaglutide deal announced this week is likely to be a catalyst for target revisions in the coming days.


# Stock Detailed Analysis Report

**LUPIN.NS**

Current Price: ₹2137.20

Generated: 2026-01-24 18:28

# LUPIN.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	12.90%	11.08%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	10.81%	2.93%
Net Income	Yes	57.80%	13.71%
ROE	No	-17.62%	-17.62%
EPS	Yes	0.27%	3.32%

# LUPIN.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Weakening Leader</b>
RS Score:	55.2/100
:	

## == RS RATIOS ==:

1M RS:	<b>1.071 [Leader]</b>
3M RS:	<b>1.155 [Leader]</b>
6M RS:	<b>1.136 [Leader]</b>
1Y RS:	<b>1.017 [Leader]</b>
:	


## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
:	


## SIGNAL CRITERIA::

✗ Emerging RS:	<b>Not accelerating</b>
✗ Medium-term Lagging:	<b>Not lagging</b>
✗ Performance Improving:	<b>Not improving</b>


**Relative Strength Analysis: LUPIN.NS vs ^CNXPHARMA**  
**Classification: Weakening Leader**  
**Price Performance Comparison (Normalized)**



**RS Ratio Trends (Multiple Timeframes)**




**RS Composite Score Timeline**



## LUPIN.NS - EMA Crossover Summary

<b>EMA 20:</b>	2151.50
<b>EMA 50:</b>	2109.47
<b>EMA 200:</b>	2023.71
<b>Trend Status:</b>	<b>Strong Uptrend</b>
<b>Golden Cross Date:</b>	2025-11-13 00:00:00+05:30
<b>Golden Cross Price:</b>	2052.90

## LUPIN.NS EMA Crossover Analysis



## LUPIN.NS - Bollinger Bands Summary

<b>Current Price:</b>	2137.20
<b>Upper Band:</b>	2237.47
<b>Middle Band (SMA 20):</b>	2151.22
<b>Lower Band:</b>	2064.98
<b>%B:</b>	0.4187
<b>Band Width:</b>	0.0802
<b>Status:</b>	Lower Half
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Sell Signal at 2025-11-17 00:00:00+05:30</b>

## LUPIN.NS Bollinger Bands (20, 2) Analysis




## **LUPIN.NS - Supertrend Summary**

**Status:** UPTREND (Buy)

**Supertrend Value:** 2097.60

**Signal Identified On:** 2025-11-12


### Supertrend Analysis for LUPIN.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## LUPIN.NS - MACD Summary

<b>MACD Line:</b>	16.92
<b>Signal Line:</b>	23.48
<b>Histogram:</b>	-6.57
<b>Trend:</b>	<b>Bearish</b>
<b>Momentum:</b>	<b>Strengthening</b>
<b>Signal:</b>	None

LUPIN.NS Price






LUPIN.NS MACD (12, 26, 9)



## LUPIN.NS - Volatility Squeeze Summary

<b>BB Width:</b>	0.0802
<b>ATR:</b>	49.4429
<b>Total Signals:</b>	37
<b>Signal 1:</b>	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Pr)
<b>Signal 2:</b>	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Pr)
<b>Signal 3:</b>	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Pr)
<b>Signal 4:</b>	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr)
<b>Signal 5:</b>	<b>BB Squeeze + ATR Contraction (Bullish Breakout) at 2026-01-06 00:00:00+05:30 (Pr)</b>


# LUPIN.NS - Volatility Squeeze Analysis



## **LUPIN.NS - RSI-Volume Summary**

<b>Current RSI:</b>	49.01
<b>Current Volume:</b>	578417
<b>Volume MA 20:</b>	814532
<b>Bullish Divergences:</b>	0
<b>Bearish Divergences:</b>	3
<b>Bearish Div 1:</b>	Date: 2025-04-28 00:00:00+05:30, Price: 2092.39
<b>Bearish Div 2:</b>	Date: 2025-12-22 00:00:00+05:30, Price: 2126.30

# LUPIN.NS RSI-Volume Divergence Analysis



# LUPIN.NS - Volume Analysis

## == VOLUME ANALYSIS ==:

**Status:** 40 Signals Detected

:

**2026-01-13 [-]:** Distribution Day



**2026-01-16 [-]:** Distribution Day

**2026-01-19 [-]:** Distribution Day

**2026-01-20 [-]:** Distribution Day

**2026-01-21 [-]:** Distribution Day

## LUPIN.NS - Volume Analysis



## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	2025.98	2137.2	2025-12-01
1 Day	UPTREND (Buy)	2097.6	2137.2	2025-11-12
15 Min	DOWNTREND (Sell)	2159.21	2142.4	2026-01-23

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bearish	Strengthening	No Signal
15 Min	Bearish	Weakening	No Signal

### LUPIN.NS - 1 Week (Candlestick + EMAs)



### LUPIN.NS - 1 Day (Candlestick + EMAs)



### LUPIN.NS - 15 Min (Candlestick + EMAs)



# Trendlyne Snapshot - LUPIN\_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More ▾

Search Stock, IPO, MF A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [LUPIN LTD.](#)

## Lupin Ltd.

NSE: LUPIN | BSE: 500257  
Lupin Live Share Price Today, Share Analysis and Chart

Mid-range Performer In 1 Starfolio Basket

**2137.20** -26.00 (-1.20%) Near 52W High of ₹2226.30

**593.6K** NSE+BSE Volume  
NSE 23 Jan, 2026 3:31 PM (IST)

ABOUT Established in 1968, Lupin is a global pharmaceutical company focused on developing and distributing a diverse range of healthcare products. Its portfolio includes generics, branded generics, complex generics, APIs, biosimilars, and specialty medicines... [Read More](#)

Watchlist Portfolio Alert My Notes [TRADE STOCK](#)

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

Durability score **70.0** /100 High Financial Strength

Valuation Score **42.0** /100 Mid Valuation

Momentum Score **59.1** /100 Technically Neutral

Analyst Price Target **2,306** 1Yr Price target upside is 8% [DVM](#)

Mid-range Performer These stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to... [View Similar](#) Embed DVM

**28** **3** **3** SWOT Analysis

**Check Before You Buy** [VIEW FULL CHECKLIST](#)  
High rank **17** Positive \* **6** Negative 73.9% Pass in checklist

**PE Valuation Check**  
Right Now Undervalued **133%** 1 Year Forward Undervalued **141.8%**

**INSIGHT** High 5Yr PE Avg of 52.6 may distort upside values.

**Lupin Key Metrics**

ROE Ann. %  High in industry	Broker Average Target  9.84% upside	Market Capitalization  High in industry	Price to Book  Above Industry Median
19.1	2,347.55	97,627	

Preset Metrics

Key Metrics  
Price Chart  
Forecaster  
Financials  
Technicals  
Shareholding  
Deals  
Documents  
Corporate actions  
Company Profile X

## Trendlyne Snapshot - LUPIN\_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)

Search Stock, IPO, MF [India](#) [A](#)

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [LUPIN LTD.](#)

**Lupin Ltd.** [ⓘ](#)

NSE: LUPIN | BSE: 500257

■ ■ ■ Mid-range Performer [ⓘ](#) ○ In 1 Starfolio Basket

[Download real time STOCK REPORT](#)

**2137.20** -26.00 (-1.20%)  
↑ Near 52W High of ₹2226.30

**593.6K** NSE+BSE Volume  
NSE 23 Jan, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes [TRADE STOCK](#)

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

### Lupin - LUPIN - stock price prediction, stock forecast, target price, analyst ratings from 37 analysts

Lupin has a share price target of Rs 2306, revenue growth forecast of 14.8%, and profit growth estimate of 37.7% for FY26, based on top 37 analyst calls.

### Lupin FORECASTER - Analyst Estimates [ⓘ](#)

[FORECASTER DASHBOARD](#) [↗](#)

